Immunotherapy in NSCLC Patients with Brain Metastases

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective...

Descripción completa

Detalles Bibliográficos
Autores principales: Buriolla, Silvia, Pelizzari, Giacomo, Corvaja, Carla, Alberti, Martina, Targato, Giada, Bortolot, Martina, Torresan, Sara, Cortiula, Francesco, Fasola, Gianpiero, Follador, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267075/
https://www.ncbi.nlm.nih.gov/pubmed/35806080
http://dx.doi.org/10.3390/ijms23137068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267075/
https://www.ncbi.nlm.nih.gov/pubmed/35806080
http://dx.doi.org/10.3390/ijms23137068

Ejemplares similares